First Author: M.Gomez Resa SPAIN
Co Author(s): P. Rocha-Cabrera
Back to previous
To report the development of bilateral macular neurosensory retinal detachments in patients with metastatic cutaneous melanoma undergoing systemic therapy with MEK inhibitors (cobimetinib) and vemurafenib enrolled in clinical trials.
Tertiary care hospital.
We report 3 cases of patients who developed subfoveal neurosensory retinal detachment following treatment with MEK inhibitors while enrolled in clinical trials for metastatic cutaneous melanoma. In each case, the toxic adverse effect occurred within the first two months after initiation of drug therapy, presented with minimal or mild visual symptoms, except in one case, who associated a significant vision lost due to a severe macular retinal detachment.
In this series, we report the detailed clinical findings of bilateral subfoveal neurosensory retinal detachment associated with MEK inhibitor use for treatment of metastatic cutaneous cancer. It is important for ophthalmologists and oncologists to be aware of the course and the management of this generally mild and self-limiting condition.